A supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) received FDA approval for efficacy on April 24, 2026. This approval was granted to Merck Sharp Dohme, expanding the drug's approved uses based on new efficacy data.
Background
The drug Keytruda Qlex is a combination product consisting of pembrolizumab and berahyaluronidase alfa-pmph. This supplemental application, identified as BLA 761467 S-3, was submitted by the sponsor, Merck Sharp Dohme, and received approval specifically for its efficacy. Supplemental approvals are a standard regulatory mechanism for modifying or expanding the approved uses of an existing biological product.
What this means
This supplemental approval for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) indicates that the FDA has reviewed and accepted additional data supporting the efficacy of this specific formulation. Supplemental applications are a standard regulatory pathway for pharmaceutical companies, such as Merck Sharp Dohme, to expand the approved uses of an already authorized drug. These applications can lead to various label changes, including new indications for treating different diseases, expanded patient populations (e.g., for earlier lines of therapy), or even new methods of administration that improve patient convenience or drug delivery. While the specific details of the expanded efficacy claim for Keytruda Qlex are not provided in the current data, the approval itself confirms that the agency found sufficient evidence to support the new use or benefit. This regulatory milestone allows Merck Sharp Dohme to update the prescribing information for Keytruda Qlex, reflecting the newly approved efficacy data and potentially broadening its clinical application and impact on patient care. Clinicians and researchers will monitor future updates to the drug's label to understand the full scope of this expanded approval.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 761467 S-3 for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) was posted on April 24, 2026, on accessdata.fda.gov.